{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:39:27Z","timestamp":1794656367174,"version":"4.9.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jhep.2023.10.029","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:08:28Z","timestamp":1698390508000},"page":"352-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Adeno-associated viruses for gene therapy \u2013 clinical implications and liver-related complications, a guide for hepatologists"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-8369","authenticated-orcid":false,"given":"Marcus Maximilian","family":"M\u00fccke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-4146","authenticated-orcid":false,"given":"Sylvia","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jhep.2023.10.029_bib1","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jhep.2023.10.029_bib2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for liver disease associated with alpha(1)-antitrypsin deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jhep.2023.10.029_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.10.029_bib4","unstructured":"U.S. Food and Drug Administration. Approved cellular and gene therapy products from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products; last accessed 25\/01\/2025."},{"key":"10.1016\/j.jhep.2023.10.029_bib5","unstructured":"European Medicine Agency. Approved cellular and gene therapy products from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/advanced-therapy-medicinal-products-overview; last accessed 25\/01\/2025."},{"issue":"11","key":"10.1016\/j.jhep.2023.10.029_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrd.2017.212","article-title":"Landmark gene therapy poised for US approval","volume":"16","author":"Morrison","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.jhep.2023.10.029_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.jhep.2023.10.029_bib8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2023.10.029_bib9","article-title":"Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B [abstract]","volume":"5","author":"Schmidt","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jhep.2023.10.029_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"10.1016\/j.jhep.2023.10.029_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00391-17","article-title":"Adeno-associated virus (AAV) serotypes have distinctive interactions with domains of the cellular AAV receptor","volume":"91","author":"Pillay","year":"2017","journal-title":"J\u00a0Virol"},{"issue":"9","key":"10.1016\/j.jhep.2023.10.029_bib12","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/jvi.63.9.3822-3828.1989","article-title":"Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression","volume":"63","author":"Samulski","year":"1989","journal-title":"J\u00a0Virol"},{"issue":"7\u20138","key":"10.1016\/j.jhep.2023.10.029_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/hum.2022.050","article-title":"Human and insect cell-produced recombinant adeno-associated viruses show differences in genome heterogeneity","volume":"33","author":"Tran","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.jhep.2023.10.029_bib14","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic\u00a0modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2023.10.029_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.omtm.2019.08.015","article-title":"Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer","volume":"15","author":"Pipe","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.jhep.2023.10.029_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol Med"},{"issue":"4","key":"10.1016\/j.jhep.2023.10.029_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.10.029_bib18","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhep.2023.10.029_bib19","article-title":"Frequency, location, and nature of AAV vector insertions after long-term follow up of FVIII transgene delivery in a hemophilia A dog model","author":"Batty","year":"2020","journal-title":"Research and practice in thrombosis and haemostasis"},{"issue":"6","key":"10.1016\/j.jhep.2023.10.029_bib20","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2023.10.029_bib21","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"7961","key":"10.1016\/j.jhep.2023.10.029_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","article-title":"Adeno-associated virus 2 infection in children with non-A-E hepatitis","volume":"617","author":"Ho","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2022.05.001","article-title":"The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far","volume":"77","author":"M\u00fccke","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2023.10.029_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.gt.3303037","article-title":"Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice","volume":"15","author":"Petry","year":"2008","journal-title":"Gene Ther"},{"issue":"9","key":"10.1016\/j.jhep.2023.10.029_bib26","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"25","key":"10.1016\/j.jhep.2023.10.029_bib27","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/blood.2022016359","article-title":"Lifelong gene therapy in dogs with hemophilia A","volume":"140","author":"Pipe","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jhep.2023.10.029_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jhep.2023.10.029_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"10.1016\/j.jhep.2023.10.029_bib30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1908993","article-title":"Current and future options of haemophilia A treatments","volume":"21","author":"Miesbach","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"13","key":"10.1016\/j.jhep.2023.10.029_bib31","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2023.10.029_bib32","article-title":"Gene therapy for hemophilia-opportunities and risks","author":"Miesbach","year":"2022","journal-title":"Dtsch Arztebl Int"},{"issue":"25","key":"10.1016\/j.jhep.2023.10.029_bib33","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib34","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"21","key":"10.1016\/j.jhep.2023.10.029_bib35","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.10.029_bib36","unstructured":"The National Library of Medicine. www.clincialtrials.gov (last accessed on 14 January 2023)."},{"issue":"11","key":"10.1016\/j.jhep.2023.10.029_bib37","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.10.029_bib38","unstructured":"Roctavian, INN-valoctocogene roxaparvovec. European Medicines agency. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roctavian-epar-product-information_en.pdf (Accessed on January 14, 2022)."},{"issue":"8","key":"10.1016\/j.jhep.2023.10.029_bib39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jhep.2023.10.029_bib40","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.10.029_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"Shahani","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.jhep.2023.10.029_bib43","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1046\/j.1538-7836.2003.00265.x","article-title":"Gene therapy for the hemophilias","volume":"1","author":"VandenDriessche","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jhep.2023.10.029_bib44","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.jhep.2023.10.029_bib45","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jhep.2023.10.029_bib46","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2023.10.029_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhep.2023.10.029_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhep.2023.10.029_bib49","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","volume":"30","author":"Butterfield","year":"2022","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jhep.2023.10.029_bib51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"issue":"24","key":"10.1016\/j.jhep.2023.10.029_bib52","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jhep.2023.10.029_bib53","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T cells","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jhep.2023.10.029_bib54","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.jhep.2023.10.029_bib55","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2023.10.029_bib56","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jhep.2023.10.029_bib57","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.10.029_bib59","series-title":"Gene therapy of hemophilia: recommendations from the German, Austrian, and Swiss society for thrombosis and haemostasis research (GTH)","author":"Miesbach","year":"2022"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2023.10.029_bib61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2023.10.029_bib62","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa2214084","article-title":"Gene therapy in patients with the crigler-najjar syndrome","volume":"389","author":"D'Antiga","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2023.10.029_bib63","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"European association for the study of the L. EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.10.029_bib64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(23)00457-9","article-title":"Mycophenolate mofetil is superior to azathioprine for the induction of remission in treatment-naive autoimmune hepatitis [CAMARO trial]","volume":"78","author":"Snijders","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib65","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1186\/s13063-022-06890-w","article-title":"Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial","volume":"23","author":"Snijders","year":"2022","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.jhep.2023.10.029_bib66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/jlts.2002.33456","article-title":"Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial","volume":"8","author":"Volpin","year":"2002","journal-title":"Liver Transpl"},{"issue":"227","key":"10.1016\/j.jhep.2023.10.029_bib67","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.jhep.2023.10.029_bib68","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.jhep.2023.10.029_bib69","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.jhep.2023.10.029_bib70","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"issue":"17","key":"10.1016\/j.jhep.2023.10.029_bib71","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.029_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ymthe.2006.03.008","article-title":"Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver","volume":"14","author":"Bell","year":"2006","journal-title":"Mol Ther"},{"issue":"5837","key":"10.1016\/j.jhep.2023.10.029_bib73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jhep.2023.10.029_bib74","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/mt.2012.197","article-title":"Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity","volume":"20","author":"Rosas","year":"2012","journal-title":"Mol Ther"},{"issue":"28","key":"10.1016\/j.jhep.2023.10.029_bib75","doi-asserted-by":"crossref","first-page":"11264","DOI":"10.1073\/pnas.1117032109","article-title":"Induction of hepatocellular carcinoma by in\u00a0vivo gene targeting","volume":"109","author":"Wang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jhep.2023.10.029_bib76","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/mt.2014.240","article-title":"Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates","volume":"23","author":"Walia","year":"2015","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.jhep.2023.10.029_bib77","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.jhep.2023.10.029_bib78","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ymthe.2005.03.020","article-title":"No evidence for tumorigenesis of AAV vectors in a large-scale study in mice","volume":"12","author":"Bell","year":"2005","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.jhep.2023.10.029_bib79","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2023.10.029_bib80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.omtm.2020.11.015","article-title":"Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors","volume":"20","author":"Ferla","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhep.2023.10.029_bib81","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2023.10.029_bib82","series-title":"Investigation finds hemophilia gene therapy likely did not cause hepatocellular carcinoma ASH clinical news","year":"2021"},{"issue":"4","key":"10.1016\/j.jhep.2023.10.029_bib83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajh.2830370406","article-title":"Hepatocellular carcinoma in hemophilia","volume":"37","author":"Colombo","year":"1991","journal-title":"Am J Hematol"},{"issue":"10097","key":"10.1016\/j.jhep.2023.10.029_bib84","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhep.2023.10.029_bib85","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823052297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823052297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T17:12:38Z","timestamp":1739553158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823052297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0168827823052297"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.10.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated viruses for gene therapy \u2013 clinical implications and liver-related complications, a guide for hepatologists","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}